anonymous
Guest
anonymous
Guest
As a long-term investor, please kill Neuroscience and focus on cancer.
True, those of us who continue to invest in DNA (Roche) have done so because of Genentech's prowess in cancer. Unfortunately, the Neuroscience portfolio is filled with a lot of me toos (brain impermeant Abs) and wacky targets like DRK that have no genetic validation. Sad.As a long-term investor, please kill Neuroscience and focus on cancer.
Heard this quote in the past regarding other failed Roche products. All fine until it's not.After Merck canned it's high-profile BACE program, our own VP of Neuroscience, MS, was quoted as saying, "Let me start by saying that I fully believe in the amyloid hypothesis, and I think it's going to be vindicated completely within years."
Oh, really? Sure you're not merely protecting your million dollar annual salary with this hyperbole BS?
As a long-term investor, please kill Neuroscience and focus on cancer.
LMAO..a “long term investor” coming to CafePharma to discuss. Uh huh...go away competitor you look like a fool with this troll.